Here the authors reveal that the prostate cancer risk variant rs4519489 enhances binding of the oncogenic transcription factor USF1, upregulating NOL10. Elevated NOL10 promotes tumor progression, highlighting the rs4519489–USF1–NOL10 axis as a potential biomarker and therapeutic target.